Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma

British Journal of Haematology, Journal Year: 2024, Volume and Issue: unknown

Published: July 22, 2024

Summary URBAN is a multicentric, ambispective study evaluating the effectiveness and safety of obinutuzumab‐based immuno‐chemotherapy maintenance in patients with untreated advanced follicular lymphoma (FL). The began before COVID‐19 emergency declaration Italy. It currently ongoing for follow‐up, enrolment timeline encompassed different stages pandemic, various vaccination roll‐out phases prevalence SARS‐CoV‐2 variants. Outcomes interest present sub‐analysis included infection rates COVID‐19‐related hospitalizations/deaths. At data cut‐off, 86 (28.8%) 213 (71.2%) were treated during/after outbreak respectively; 294 (98.3%) completed induction, 31 (10.4%) 170 (56.9%) still on maintenance. Overall, 245 (81.9%) received at least one vaccine dose: 13.5%, 31.4% 55.1% one, two three doses respectively. We observed substantial decrease mortality pre‐ versus post‐vaccination phases, along reduction outcomes due to shift from alpha/delta omicron variant predominance. No differences emerged between given or not, although schedule was modified 65% cases. To our knowledge, represents largest dataset FL extensively exposed obinutuzumab. ClinicalTrials.gov identifier: NCT04034056.

Language: Английский

Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1207 - 1207

Published: Oct. 24, 2024

Cancer patients face a greater risk of complications and death after contracting the SARS-CoV-2 virus. Booster doses COVID-19 vaccine were suggested to provide additional protection. This study aimed assess how cancer patients' immune systems respond booster shots categorize their responses.

Language: Английский